CN113072470B - N-acetonitrile bis-benzenesulfonylimine derivative and preparation method and application thereof - Google Patents
N-acetonitrile bis-benzenesulfonylimine derivative and preparation method and application thereof Download PDFInfo
- Publication number
- CN113072470B CN113072470B CN202110342964.4A CN202110342964A CN113072470B CN 113072470 B CN113072470 B CN 113072470B CN 202110342964 A CN202110342964 A CN 202110342964A CN 113072470 B CN113072470 B CN 113072470B
- Authority
- CN
- China
- Prior art keywords
- formula
- acetonitrile
- derivative
- synthesizing
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 56
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 33
- 239000003054 catalyst Substances 0.000 claims abstract description 18
- 239000000654 additive Substances 0.000 claims abstract description 15
- 230000000996 additive effect Effects 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 7
- 150000002367 halogens Chemical class 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- 238000001308 synthesis method Methods 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- 230000002194 synthesizing effect Effects 0.000 claims description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 239000012074 organic phase Substances 0.000 claims description 15
- 239000003208 petroleum Substances 0.000 claims description 15
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims description 14
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical group [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims description 14
- 229940045803 cuprous chloride Drugs 0.000 claims description 14
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical group C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 13
- 238000010898 silica gel chromatography Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 11
- 239000003480 eluent Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- 230000035484 reaction time Effects 0.000 claims description 5
- BTEJSUVVNDDTPL-UHFFFAOYSA-N n-fluoro-n-phenylbenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)C1=CC=CC=C1 BTEJSUVVNDDTPL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- CJYQZTZSYREQBD-UHFFFAOYSA-N n-fluorobenzenesulfonamide Chemical compound FNS(=O)(=O)C1=CC=CC=C1 CJYQZTZSYREQBD-UHFFFAOYSA-N 0.000 claims 1
- 238000010189 synthetic method Methods 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- -1 trifluoromethoxy, acetyl Chemical group 0.000 abstract description 17
- 230000009471 action Effects 0.000 abstract description 6
- 239000006227 byproduct Substances 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 125000004185 ester group Chemical group 0.000 abstract description 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 3
- HNVRRHSXBLFLIG-UHFFFAOYSA-N 3-hydroxy-3-methylbut-1-ene Chemical compound CC(C)(O)C=C HNVRRHSXBLFLIG-UHFFFAOYSA-N 0.000 description 11
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 238000007333 cyanation reaction Methods 0.000 description 9
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000004821 distillation Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- UEQYFPCXXRUPKQ-UHFFFAOYSA-N azidoethene Chemical compound C=CN=[N+]=[N-] UEQYFPCXXRUPKQ-UHFFFAOYSA-N 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- BZAZNULYLRVMSW-UHFFFAOYSA-N 2-Methyl-2-buten-3-ol Natural products CC(C)=C(C)O BZAZNULYLRVMSW-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HQSWZFCOUPABJQ-UHFFFAOYSA-N [C].CC#N Chemical compound [C].CC#N HQSWZFCOUPABJQ-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- QEJDLQGIDJNJTI-UHFFFAOYSA-N C=1C=CC=CC=1N(S(=O)=O)C1=CC=CC=C1 Chemical class C=1C=CC=CC=1N(S(=O)=O)C1=CC=CC=C1 QEJDLQGIDJNJTI-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- HZUWQPSNEHSEOD-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-3-methyl-2-oxo-1,3-benzoxazole-6-sulfonamide Chemical compound C1=C2OC(=O)N(C)C2=CC=C1S(=O)(=O)NC1=CC=C(Cl)C(Cl)=C1 HZUWQPSNEHSEOD-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000005945 von Braun degradation reaction Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/42—Separation; Purification; Stabilisation; Use of additives
- C07C303/44—Separation; Purification
Abstract
The disclosure belongs to the technical field of organic synthetic chemistry, and particularly provides an N-acetonitrile bis-benzenesulfonylimine derivative, and a preparation method and application thereof. The structure of the N-acetonitrile bis-benzenesulfonylimine derivative is shown as a formula (1),wherein R or R 1 Are all selected from one of hydrogen, halogen, C1-C6 linear chain or branched chain alkyl, C1-C6 linear chain alkoxy, nitro, ester group, trifluoromethyl, trifluoromethoxy, acetyl, condensed ring group and heterocyclic group. The synthesis method comprises the following steps: the compound shown in the formula (1) is synthesized by taking a hydroxyl alkenyl azide and N-fluoro-bis-benzenesulfonamide as raw materials under the combined action of an additive and a catalyst. The method can quickly and effectively synthesize the N-acetonitrile bis-benzenesulfonylimide derivative, has mild reaction conditions and does not have toxic by-products.
Description
Technical Field
The disclosure belongs to the technical field of organic synthetic chemistry, and particularly provides an N-acetonitrile bis-benzenesulfonylimine derivative, and a preparation method and application thereof.
Background
The statements herein merely provide background information related to the present disclosure and may not necessarily constitute prior art.
Nitrile compounds are compounds containing cyano groups (-CN), are widely present in natural products, play an important role in the aspects of medicine, functional materials, pesticide synthesis and the like, and play an important role in organic synthetic chemistry. The existing methods for synthesizing nitrile compounds include: 1. sandmeyer reaction, 1884, sandmeyer converted a diazonium salt to a cyano group using a Cu salt to form the corresponding cyano compound. 2. Rosememed-von Braun reaction, 1In 914, rosemmed reported that halogens could be converted to cyano groups under CuCN catalysis. 3. C-C coupling cyanation reaction, 2005, beller et al, was found in Cu (BF) 4 ) 2 ·6H 2 Non-toxic K in the presence of O 4 [Fe(CN) 6 ]Can be used as an anion source of cyano to perform anion exchange with aryl bromide to generate a corresponding cyanation product; in 2012, cheng topic group found that the cyano anion in DDQ was in Cu (OTf) 2 Catalytically, the catalyst can be exchanged with the boric acid ion of the arylboronic acid to form the corresponding cyanation product. 4. C-H bond cyanation reaction, 2014, liu reported that CuCN provides cyano anion, 2-aryl pyridine in Cu (OAC) 2 Cyanidation reaction under catalysis; in 2016, shen reported on Pd (OAC) 2 Cyanation reaction of α -iminonitrile as a source of cyano groups in the presence of a catalyst; in 2019, cheng topic group uses N-alkoxy phthalimide as a substrate, utilizes light and copper for co-catalysis, and realizes the remote asymmetric cyanation reaction of C-H bonds under the irradiation of blue light. Although the cyanation reaction is carried out in various ways, these methods have disadvantages such as: the reaction conditions are harsh, the steps are complicated, the method is harmful to health, pollutes the environment and the like, so that the development of a novel method for synthesizing the nitrile compound, which has mild reaction conditions and is environment-friendly, is very important.
The vinyl azide is a molecule simultaneously containing conjugated olefin and azide groups, and the synergistic effect of the two functional groups ensures that the vinyl azide has unique properties which are not possessed by single olefin or azide groups, and can be used as an electrophilic reagent, a nucleophilic reagent, a free radical receptor and the like to participate in various reaction paths to generate various intermediates with high reactivity. Among them, the hydroxy alkenyl azide is a common reagent for cyanation reaction due to its simple and easily available structure, high reactivity, and the like. In 2017, the Cui topic group utilizes 2-methyl-3-butene-2-ol as a butyronitrile precursor to react with quinone methoxy compounds to synthesize a cyanation product. In 2020, 2-methyl-3-buten-2-ol is used as a substitute of acetonitrile carbon by the Cao project group, and Lewis acid and chiral transition metal iridium are used for catalyzing a hydroxyalkenyl azide and an asymmetric allyl electrophilic reagent to perform a coupling reaction to synthesize a nitrile compound. In recent years, research on hydroxyalkenyl azide compounds as cyanating agents has made great progress, however, the inventors of the present disclosure found in the course of research that the method for synthesizing nitriles using vinyl azide compounds is single in type and insufficient in product diversity, which seriously hinders the wide application of vinyl azide compounds as cyanating agents in organic synthesis.
Disclosure of Invention
Aiming at the problems of single type and insufficient product diversity of a method for synthesizing nitrile by using a vinyl azide in the prior art. The invention aims to provide a method for synthesizing an N-acetonitrile-based bis-benzenesulfonylimide derivative, which utilizes a novel material 2-methyl-3-butylene-2-alcohol as a substitute of acetonitrile carbon to react with N-fluoro-bis-benzenesulfonylimide under the combined action of an additive and a catalyst to quickly and effectively synthesize the N-acetonitrile-based bis-benzenesulfonylimide derivative, and has mild reaction conditions and no toxic side products.
In one or more embodiments of the present disclosure, an N-acetonitrile bis-benzenesulfonylimine derivative is provided, which has a structure shown in formula (1),
formula (1);
wherein, R or R1 is selected from one of hydrogen, halogen, C1-C6 linear chain or branched chain alkyl, C1-C6 linear chain alkoxy, nitryl, ester group, trifluoromethyl, trifluoromethoxy, acetyl, condensed ring group and heterocyclic group.
In one or some embodiments of the present disclosure, there is provided a method for synthesizing a compound of formula (1), the synthetic route of which is shown below,
in one or more embodiments of the present disclosure, there is provided a method for synthesizing a compound of formula (1), comprising the steps of: the compound shown in the formula (1) is synthesized by taking 2-methyl-3-butylene-2-alcohol and N-fluoro-bis-benzenesulfonamide as raw materials under the combined action of an additive and a catalyst.
In one or more embodiments of the present disclosure, there is provided the use of a compound as described above or a method of synthesizing a compound of formula (1) as described above for the preparation of an anti-inflammatory agent.
One or some of the above technical solutions have the following advantages or beneficial effects:
1) The method takes novel material 2-methyl-3-butylene-2-alcohol as raw material for the first time, and the raw material reacts with N-fluoro-diphenyl sulfonamide under the combined action of a catalyst and an additive to generate the N-acetonitrile-based diphenyl sulfonamide derivative. The method disclosed by the invention has the advantages of easily available raw materials, simplicity in operation, mild conditions, high yield, no toxic by-product generation, few reaction steps, environmental friendliness and suitability for large-scale industrial production.
2) The N-cyanobenzene sulfonyl imide is synthesized for the first time, and through detection, the N-cyanobenzene sulfonyl imide has anti-inflammatory activity, not only enriches the drug properties of the N-cyanobenzene sulfonyl imide derivative, but also gives full play to the advantages of the N-cyanobenzene sulfonyl imide derivative in the field of drug synthesis chemistry.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this disclosure, illustrate embodiments of the disclosure and, together with the description, serve to explain the disclosure and not to limit the disclosure.
FIG. 1 is a drawing of compound 1c prepared according to examples 1 to 5 of the present disclosure 1 Nuclear magnetic resonance spectrum of H-NMR;
FIG. 2 is a drawing of compound 1c prepared in examples 1-5 of the present disclosure 13 Nuclear magnetic resonance spectrum of C-NMR;
Detailed Description
The technical solutions in the embodiments of the present disclosure will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present disclosure, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments of the disclosure without making any creative effort, shall fall within the protection scope of the disclosure.
Aiming at the problems of single type and insufficient product diversity of a method for synthesizing nitrile by using a vinyl azide in the prior art. The invention aims to provide a method for synthesizing an N-acetonitrile-based bis-benzenesulfonylimine derivative, which utilizes a novel material 2-methyl-3-butylene-2-alcohol as a substitute of acetonitrile carbon to react with N-fluoro-bis-benzenesulfonylimine under the combined action of an additive and a catalyst to quickly and effectively synthesize the N-acetonitrile-based bis-benzenesulfonylimine derivative, and has the advantages of mild reaction conditions and no toxic side products.
In one or more embodiments of the present disclosure, an N-acetonitrile bis-benzenesulfonylimide derivative is provided, which has a structure shown in formula (1),
formula (1);
wherein, R or R1 is selected from one of hydrogen, halogen, C1-C6 linear chain or branched chain alkyl, C1-C6 linear chain alkoxy, nitro, ester group, trifluoromethyl, trifluoromethoxy, acetyl, condensed ring group and heterocyclic group.
Preferably, the halogen is selected from one of F, cl, br and I;
or, said C 1 -C 6 The linear alkyl is selected from one of methyl, ethyl, n-propyl and n-butyl;
or, the branched alkyl is selected from one of tert-butyl and n-pentyl;
or, said C 1 -C 2 The linear alkoxy is selected from one of methoxy and ethoxy.
In one or some embodiments of the present disclosure, there is provided a method for synthesizing a compound of formula (1), the synthetic route of which is shown below,
in one or more embodiments of the present disclosure, there is provided a method for synthesizing a compound of formula (1), comprising the steps of: the compound shown in the formula (1) is synthesized by taking 2-methyl-3-butylene-2-alcohol and N-fluoro-diphenyl sulfonamide as raw materials under the combined action of an additive and a catalyst.
The chemical formula of the 2-methyl-3-butylene-2-alcohol isThe chemical formula of the N-fluoro-diphenyl sulfonamide is
Preferably, the additive is one of 1, 10-phenanthroline (Phen), benzoic acid (PhCOOH) and trifluoroacetic acid (TFA); preferably, the additive is Phen; when Phen is added, the conversion of the starting material and the yield of the product can be increased.
Or the catalyst is cuprous chloride (CuCl), cuprous iodide (CuI), or cupric chloride (CuCl) 2 ) Copper acetate (Cu (OAc) 2 ) One of copper oxide (CuO), cuprous cyanide (CuCN), and cuprous bromide (CuBr); preferably, the catalyst is CuCl. When the catalyst is CuCl, the conversion rate of raw materials and the yield of products can be improved.
The N-acetonitrile bisbenzenesulfonylimine derivative is prepared by taking novel materials 2-methyl-3-butylene-2-alcohol and N-fluoro bisbenzenesulfonyl amide as raw materials under the catalysis of cuprous. The method disclosed by the invention has the advantages of few steps, simplicity in operation, easiness in obtaining raw materials, mild reaction conditions, high yield and no toxic by-product.
Preferably, the reaction temperature is 20-60 ℃, and preferably, the reaction temperature is 50 ℃; the reaction temperature is 20-60 ℃. This temperature can increase the conversion of the feedstock while increasing the yield of the product. When the reaction is carried out at 50 ℃, the conversion of the raw material and the yield of the product can be further improved.
Or the reaction time is 0-24 h and is not 0; preferably, the reaction time is 16. + -. 0.1h.
Preferably, the raw materials are added into a solvent to be dissolved, then the additive and the catalyst are added, and the reaction is carried out in a heating environment;
preferably, the solvent is dimethyl sulfoxide (DMSO), acetonitrile (CH) 3 CN), N-Dimethylformamide (DMF), toluene (PhMe) and Dichloromethane (DCM);
further preferably, the solvent is DCM.
Preferably, the molar ratio of the 2-methyl-3-buten-2-ol to the N-fluorobisbenzenesulfonamide is 1 to 2:1 to 3. Further preferred, the molar ratio of 2-methyl-3-buten-2-ol to N-fluorobisbenzenesulfonamide is 1:1.5.
preferably, the amount of the catalyst added is 0 to 1 time the molar mass of the hydroxyalkenyl azide compound. More preferably, the amount of the catalyst added is 0.2 times the molar mass of the hydroxyalkenyl azide compound.
Preferably, the additive is added in an amount of 1 to 3 times the molar mass of 2-methyl-3-buten-2-ol. More preferably, the additive is added in an amount of 2 times the molar mass of 2-methyl-3-buten-2-ol.
Preferably, adding an extraction solvent into the solution after the reaction for extraction to obtain an organic phase, removing the solvent in the organic phase, and performing silica gel column chromatography to obtain the N-acetonitrile bis-benzenesulfonylimide derivative;
preferably, the extraction solvent adopted in the extraction is ethyl acetate;
preferably, the extraction is carried out for 1 to 3 times, and 5 to 20mL of extraction solvent is used each time;
preferably, the obtained organic phase is dried by adopting anhydrous sodium sulfate, and then the organic solvent is removed;
preferably, the eluent of the silica gel column chromatography is petroleum ether and ethyl acetate;
preferably, the volume ratio of the petroleum ether to the ethyl acetate is 1-30;
preferably, the volume ratio of petroleum ether to ethyl acetate is 20.
In one or more embodiments of the present disclosure, there is provided the use of a compound as described above or a method of synthesizing a compound of formula (1) as described above for the preparation of an anti-inflammatory agent.
Example 1
The compound 1a (0.2 mmol), compound1b (0.3 mmol,1.5 eq) was dissolved in 3mL DCM and then CuCl (0.04mmol, 0.2eq), phen (0.4mmol, 2eq) were added and reacted at 50 ℃ for 16h. The reaction was monitored by TLC and was terminated when the starting material had reacted. Pouring the reaction solution into 30mL of water, extracting with ethyl acetate (3X 10 mL), combining organic phases, drying with anhydrous sodium sulfate, filtering, removing the organic solvent by reduced pressure distillation, and performing silica gel column chromatography (eluent V) Petroleum ether :V Ethyl acetate = 20).
Example 2
Compound 1a (0.2 mmol), compound 1b (0.3 mmol,1.5 eq) were dissolved in 3mL DMF, followed by addition of CuCl (0.04mmol, 0.2eq), phen (0.4 mmol, 2eq) and reaction at 50 ℃ for 16h. The reaction was monitored by TLC and was terminated when the starting material had reacted. Pouring the reaction solution into 30mL of water, extracting with ethyl acetate (3X 10 mL), combining organic phases, drying with anhydrous sodium sulfate, filtering, removing organic solvent by reduced pressure distillation, and performing silica gel column chromatography (eluent is V) Petroleum ether :V Ethyl acetate = 20).
Example 3
Compound 1a (0.2 mmol), compound 1b (0.3 mmol,1.5 eq) were dissolved in 3mL of CCM, followed by addition of CuI (0.04mmol, 0.2eq), phen (0.4 mmol, 2eq) and reaction at 50 ℃ for 16h. The reaction was monitored by TLC and the reaction was terminated when the starting material had reacted. Pouring the reaction solution into 30mL of water, extracting with ethyl acetate (3X 10 mL), combining organic phases, drying with anhydrous sodium sulfate, filtering, removing organic solvent by reduced pressure distillation, and performing silica gel column chromatography (eluent is V) Petroleum ether :V Ethyl acetate = 20).
Example 4:
compound 1a (0.2 mmol), compound 1b (0.3 mmol,1.5 eq) were dissolved in 3mL of CCM, followed by addition of CuCl (0.04mmol, 0.2eq), phCOOH (0.4 mmol, 2eq) and reaction at 50 ℃ for 16h. The reaction was monitored by TLC and the reaction was terminated when the starting material had reacted. The reaction mixture was poured into 30mL of water, extracted with ethyl acetate (3X 10 mL), and combinedDrying the organic phase with anhydrous sodium sulfate, vacuum filtering, distilling under reduced pressure to remove organic solvent, and performing silica gel column chromatography (eluent is V) Petroleum ether :V Ethyl acetate = 20).
Example 5
Compound 1a (0.2 mmol), compound 1b (0.3 mmol,1.5 eq) were dissolved in 3mL of CCM, followed by addition of CuCl (0.04mmol, 0.2eq), phen (0.4 mmol, 2eq) and reaction at 30 ℃ for 16h. The reaction was monitored by TLC and was terminated when the starting material had reacted. Pouring the reaction solution into 30mL of water, extracting with ethyl acetate (3X 10 mL), combining organic phases, drying with anhydrous sodium sulfate, filtering, removing organic solvent by reduced pressure distillation, and performing silica gel column chromatography (eluent is V) Petroleum ether :V Ethyl acetate = 20).
The reactions of examples 1 to 5 are shown by the following formulae:
compound 1c:
1 H NMR(400MHz,CDCl 3 )δ7.97–7.89(m,4H),7.58(t,J=7.5Hz,2H),7.46(t,J=7.8Hz,4H),4.50(s,2H). 13 C NMR(101MHz,CDCl 3 )δ136.92,133.89,128.45,127.28,113.15,34.25.HRMS(ESI)m/z calculated for C 14 H 13 N 2 O 4 S 2 [M+H] + :337.0317,found:337.0329.
example 6
Compound 1a (0.2 mmol), compound 2b (0.3 mmol,1.5 eq) were dissolved in 3mL of CCM, followed by addition of CuCl (0.04mmol, 0.2eq), phen (0.4 mmol, 2eq) and reaction at 50 ℃ for 16h. The reaction was monitored by TLC and the reaction was terminated when the starting material had reacted. Pouring the reaction solution into 30mL of water, extracting with ethyl acetate (3X 10 mL), combining organic phases, drying with anhydrous sodium sulfate, filtering, removing organic solvent by reduced pressure distillation, and performing silica gel column chromatography (eluent is V) Petroleum ether :V Acetic acidEthyl ester = 20).
The reaction formula is as follows:
compound 2c:
HRMS(ESI)m/z calculated for C 14 H 10 Cl 2 N 2 O 4 S 2 [M+H] + :403.9459,found:403.9427.
example 7
Compound 1a (0.2 mmol), compound 3b (0.3 mmol,1.5 eq) were dissolved in 3mL of CCM, followed by addition of CuCl (0.04mmol, 0.2eq), phen (0.4 mmol, 2eq) and reaction at 50 ℃ for 16h. The reaction was monitored by TLC and the reaction was terminated when the starting material had reacted. Pouring the reaction solution into 30mL of water, extracting with ethyl acetate (3X 10 mL), combining organic phases, drying with anhydrous sodium sulfate, filtering, removing the organic solvent by reduced pressure distillation, and performing silica gel column chromatography (eluent V) Petroleum ether :V Ethyl acetate = 20).
The reaction formula is as follows:
compound 3c:
HRMS(ESI)m/z calculated for C 14 H 11 N 3 O 6 S 2 [M+H] + :381.0089,found:301.0034.
example 8
Compound 1a (0.2 mmol), compound 4b (0.3 mmol,1.5 eq) were dissolved in 3mL of CCM, followed by addition of CuCl (0.04mmol, 0.2eq), phen (0.4 mmol, 2eq) and reaction at 50 ℃ for 16h. The reaction was monitored by TLC and the reaction was terminated when the starting material had reacted. The reaction mixture was poured into 30mL of water, extracted with ethyl acetate (3X 10 mL), the organic phases were combined, dried over anhydrous sodium sulfate and filtered with suction, and then distilled off under reduced pressureRemoving organic solvent, and performing silica gel column chromatography (eluent is V) Petroleum ether :V Acetic acid ethyl ester = 20).
The reaction formula is as follows:
compound 4c:
HRMS(ESI)m/z calculated for C 15 H 14 N 2 O 4 S 2 [M+H] + :350.0395,found:350.0347.
example 9
Compound 1a (0.2 mmol), compound 5b (0.3 mmol,1.5 eq) were dissolved in 3mL of CCM, followed by addition of CuCl (0.04mmol, 0.2eq), phen (0.4 mmol, 2eq) and reaction at 50 ℃ for 16h. The reaction was monitored by TLC and was terminated when the starting material had reacted. Pouring the reaction solution into 30mL of water, extracting with ethyl acetate (3X 10 mL), combining organic phases, drying with anhydrous sodium sulfate, filtering, removing organic solvent by reduced pressure distillation, and performing silica gel column chromatography (eluent is V) Petroleum ether :V Acetic acid ethyl ester = 20).
The reaction formula is as follows:
compound 5c:
HRMS(ESI)m/z calculated for C 18 H 20 N 2 O 4 S 2 [M+H] + :392.0864,found:3592.0843.
example 10
This example provides an effect test of compounds 1c, 2c, 3c, 4c, and 5c in inhibiting the activity of hepatoma cells, comprising the following steps: 1. liver cancer HepG2 cells were seeded at a cell density of 6X 104/mL in a culture plate at a concentration of 100. Mu.L per well, 37 ℃ C., 5% CO 2 And incubated overnight under saturated humidity conditions.
2. After the adhesion of the membrane, the compounds 1c, 2c, 3c, 4c and 5c were added to the membrane respectively to achieve final concentrations of 1. Mu.g/ml, 2. Mu.g/ml, 3. Mu.g/ml, 4. Mu.g/ml and 5. Mu.g/ml, each set of 5 multiple wells with a final volume of 200. Mu.L per well. The control group was added with an equal amount of DMEM medium.
3. After 24 hours and 48 hours of incubation, 30. Mu.L of MTT (5 mg/mL)) was added to each well and incubation was continued for 6 hours.
4. The supernatant was centrifuged off and 150. Mu.L of DMSO was added to each well to dissolve the crystalline particles.
5. And (3) measuring the absorbance (D) by the enzyme-labeling instrument at the wavelength of 580nm, calculating the proliferation inhibition rate of the cervical cancer HeLa cells by the adriamycin with different time and different concentration, and repeating the experiment for 3 times.
6. The growth inhibition rate = [ (control D570 — experimental D570)/control D570] × 100% was calculated. IC50 refers to the concentration of drug required to reduce the number of cells that survive a drug administration by half. In the MTT method, the IC50 is the concentration of the drug required to reduce the OD value of the absorbance of the control group by half.
In addition, the meaning of median inhibitory concentration corresponds to the average of the minimum lethal doses of drugs on cultured cells, and is widely used in screening various drugs as a quantitative index reflecting the drug efficacy.
Specifically, according to the formula: inhibition = 1-addition group OD value/control group OD value, calculated IC50 values of the compounds tested, all compounds had IC50 values below 6.3 μ g/kg,
the disclosure of the present invention is not limited to the specific embodiments, but rather to the specific embodiments, the disclosure is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (14)
1. A synthetic method of a compound shown in a formula (1) of an N-acetonitrile-based bis-benzenesulfonylimine derivative is characterized in that the structure of the N-acetonitrile-based bis-benzenesulfonylimine derivative is shown in the formula (1),
formula (1);
wherein, R or R1 is selected from one of hydrogen, halogen, C1-C6 linear chain or branched chain alkyl, C1-C6 linear chain alkoxy, nitro, trifluoromethyl, trifluoromethoxy and acetyl;
the halogen is selected from one of F, cl, br and I;
the C1-C6 linear alkyl is selected from one of methyl, ethyl, n-propyl, n-butyl and n-pentyl;
the branched alkyl is tert-butyl;
the straight chain alkoxy of the C1-C2 is selected from one of methoxy and ethoxy;
the synthetic route of the compound represented by the formula (1) is shown below,
the synthesis method of the compound shown in the formula (1) comprises the following steps:
taking 1a and N-fluoro-diphenyl sulfonamide as raw materials, adding the raw materials into a solvent for dissolving, then adding an additive and a catalyst, and reacting in a heating environment to synthesize a compound shown in a formula (1);
the additive is 1, 10-phenanthroline;
the solvent is dichloromethane;
the catalyst is cuprous chloride.
2. The method for synthesizing a compound represented by the formula (1) which is an N-acetonitrile bisbenzenesulfonylimide derivative according to claim 1, wherein the reaction temperature is 20 to 60 ℃, the reaction time is 0 to 24h, and the reaction time is not 0.
3. The method for synthesizing the compound of formula (1) of N-acetonitrile bis-benzenesulfonylimide derivative according to claim 1, wherein the reaction temperature is 50 ℃ and the reaction time is 16 ± 0.1h.
4. The method for synthesizing the compound of the N-acetonitrile-based bisbenzenesulfonylimide derivative represented by the formula (1) according to claim 1, wherein the molar ratio of 1a to N-fluorobenzenesulfonamide is 1 to 2:1 to 3; the addition amount of the catalyst is 0 to 1 time of the 1a molar mass, and the addition amount is not 0; the additive is added in an amount of 1 to 3 times the molar mass of 1 a.
5. The method for synthesizing the compound of formula (1) which is an N-acetonitrile bisbenzenesulfonylimide derivative according to claim 4, wherein the molar ratio of 1a to N-fluorobisbenzenesulfonylimide is 1:1.5.
6. the method for synthesizing the compound represented by the formula (1) of the N-acetonitrile-based bisbenzenesulfonylimide derivative of claim 4, wherein the amount of the catalyst added is 0.2 times the molar mass of 1 a.
7. The method for synthesizing a compound represented by the formula (1) of an N-acetonitrile-based bisbenzenesulfonylimide derivative as claimed in claim 4, wherein the amount of the additive added is 2 times the molar mass of 1 a.
8. The method for synthesizing the compound represented by the formula (1) of the N-acetonitrile-based bisbenzenesulfonylimide derivative according to claim 1, wherein the solution after the reaction is added with an extraction solvent to extract the solution to obtain an organic phase, the solvent in the organic phase is removed, and silica gel column chromatography is performed to obtain the N-acetonitrile-based bisbenzenesulfonylimide derivative.
9. The method for synthesizing the compound represented by the formula (1) of the N-acetonitrile-based bis-benzenesulfonylimine derivative according to claim 8, wherein the extraction solvent used for the extraction is ethyl acetate.
10. The method for synthesizing the compound of formula (1) of N-acetonitrile bisbenzenesulfonylimide derivative according to claim 8, wherein the extraction is performed 1 to 3 times by using 5 to 20mL of the extraction solvent each time.
11. The method for synthesizing the compound represented by the formula (1) of the N-acetonitrile bisbenzenesulfonylimide derivative of claim 8, wherein the organic phase obtained is dried over anhydrous sodium sulfate, and the organic solvent is removed.
12. The method for synthesizing the compound represented by the formula (1) of the N-acetonitrile bisbenzenesulfonylimide derivative according to claim 8, wherein the eluent for the silica gel column chromatography is petroleum ether or ethyl acetate.
13. The method for synthesizing the compound of formula (1) of the N-acetonitrile bisbenzenesulfonylimide derivative according to claim 12, wherein the volume ratio of petroleum ether to ethyl acetate is 1 to 30.
14. The method for synthesizing the compound of formula (1) of the N-acetonitrile bisbenzenesulfonylimide derivative according to claim 12, wherein the volume ratio of petroleum ether to ethyl acetate is 20.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110342964.4A CN113072470B (en) | 2021-03-30 | 2021-03-30 | N-acetonitrile bis-benzenesulfonylimine derivative and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110342964.4A CN113072470B (en) | 2021-03-30 | 2021-03-30 | N-acetonitrile bis-benzenesulfonylimine derivative and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113072470A CN113072470A (en) | 2021-07-06 |
CN113072470B true CN113072470B (en) | 2023-01-13 |
Family
ID=76611976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110342964.4A Expired - Fee Related CN113072470B (en) | 2021-03-30 | 2021-03-30 | N-acetonitrile bis-benzenesulfonylimine derivative and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113072470B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023048237A1 (en) * | 2021-09-22 | 2023-03-30 | Agc株式会社 | Amino fluorinating agent and method for producing amino fluorinating agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015130922A2 (en) * | 2014-02-26 | 2015-09-03 | The Trustees Of The University Of Pennsylvania | Small molecule hsp70 inhibitors |
CN107652207B (en) * | 2017-10-10 | 2020-09-22 | 陈静 | Synthetic method of 1-amino-1-cyclopropanecarbonitrile hydrochloride |
CN111517904B (en) * | 2020-02-10 | 2022-12-27 | 台州学院 | Preparation method of sulfonyl acetonitrile compound |
-
2021
- 2021-03-30 CN CN202110342964.4A patent/CN113072470B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN113072470A (en) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108047198B (en) | Method for preparing polyaryl substituted naphthalene derivative by reaction of aryl ketone and tolane under catalysis of ruthenium | |
WO2021169359A1 (en) | Benzodihydrofuro heterocyclic compound and preparation method therefor | |
CN111690947B (en) | Electrochemical synthesis method of trifluoromethylated aryl amide derivative | |
CN105001031B (en) | Ionic iron (III) coordination compound containing single phenol functionalization Imidazole cation and preparation method and application | |
CN105175328A (en) | Method for synthesizing quinoline derivative by utilizing arylamine, aromatic aldehyde and ketone | |
CN113072470B (en) | N-acetonitrile bis-benzenesulfonylimine derivative and preparation method and application thereof | |
CN113105357B (en) | Synthesis method and application of novel p-aryl azophenol derivative | |
CN104447336B (en) | A kind of three dish ene derivatives and preparation method thereof | |
CN114874139B (en) | Synthesis method of 1-benzyl or allyl 3, 4-dihydroisoquinoline | |
CN113416162B (en) | Double-chiral binaphthyl O-N-N tridentate ligand and preparation method thereof | |
CN108218798B (en) | Preparation method of Apabetalone | |
CN113105401B (en) | 1, 2, 3-triazole derivative and preparation method and application thereof | |
CN113004248B (en) | Method for synthesizing carbazole compound by catalyzing hydrocarbon amination reaction with cobalt | |
JP4360096B2 (en) | Optically active quaternary ammonium salt, method for producing the same, and method for producing optically active α-amino acid derivative using the same as phase transfer catalyst | |
CN105367481B (en) | A kind of synthetic method of bis- fluoro- 2- oxoindole derivatives of 3,3- | |
CN105924390B (en) | A kind of synthetic method of Mei Tafeini | |
CN114989063A (en) | Synthesis method of beta-halopyrrole compound | |
CN113735752A (en) | Method for preparing isothiourea compound based on substituted iodobenzene | |
EP3782977A1 (en) | Cyclopropanation method and reagent | |
CN108440373B (en) | Iron-catalyzed cyanoalkylindoline and preparation method thereof | |
CN110746336B (en) | Green preparation method of N-methyl-2-cyano-3-arylpyrrole compound | |
CN113105400B (en) | 1,2, 3-triazole derivative and preparation method and application thereof | |
CN106854125B (en) | Method for preparing α -fluoro- β -ethynyl ketone compound containing two chiral centers | |
CN114160206B (en) | Catalyst for catalytic synthesis of optically active indole compound, application and synthesis method thereof, and optically active indole compound | |
CN110746337B (en) | Synthesis method of 1-methyl-2-cyano-3-aliphatic substituted azole compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20230113 |
|
CF01 | Termination of patent right due to non-payment of annual fee |